Our International Life Sciences Transactions team includes a number of attorneys who have served as in-house counsel at life sciences companies. For many of our clients, our lawyers have assumed managerial roles, including those of director and corporate secretary, among others. Our worldwide capabilities and personal service have been integral to the success of many U.S. companies doing business abroad, and foreign companies doing business in the United States. Our team includes those versed in:
- Mergers and acquisitions
- Equity, debt and commercial finance
- Securities offerings, compliance and enforcement
- Strategic alliances
- Joint ventures
- Collaboration and licensing
- Technology transfer
- Research and development
- Product acquisition and divestitures
- Clinical trial and CRO agreements
- Manufacturing, tolling and supply arrangements
- Sales, promotion, marketing and other commercial arrangements
To provide complete answers to business concerns, we work closely with colleagues knowledgeable in U.S. and international antitrust, intellectual property, tax, commercial real estate, employment (including benefits and immigration), FDA approval and compliance, health care (including fraud and abuse compliance and price reimbursement matters), product liability, bankruptcy, and other areas.
To succeed in the life sciences arena, you need support from those who know how to listen, who understand your business, and who can create solutions based on your business goals. This is the type of support you get from Reed Smith’s Life Sciences Transactions team. Whatever your needs, Reed Smith has the team for your complex life sciences transactions.
Representative Matters
Represented a major manufacturer and marketer of products for the detection and treatment of vulnerable plaque disease, in its initial public offering of common stock. The company is listed on the NASDAQ stock exchange, and Reed Smith assisted the company in all aspects, including clearing its registration statement through the SEC.
Represented Napo Pharmaceuticals, Inc., a specialty pharmaceutical company discovering and commercializing drugs from natural sources, in connection with its initial public offering that was sponsored and underwritten by Nomura Code Securities. The project involved extensive collaboration between our Californian and London offices.
Represented a molecular diagnostics company in numerous common stock offerings, valued at $86 million, $62 million, $10 million, $28 million and $92 million.
Advised a leading provider of advanced fuel cell power solutions for sub-kilowatt portable, remote and mobile applications, as nominated adviser and broker on the flotation of a U.S. corporation, on AIM.
Represented a pharmaceutical company in the acquisition of a laboratory and manufacturing facility in Puerto Rico.
- View all...
